Biologikatherapie beim systemischen Lupus erythematodes

详细信息    查看全文

• 作者：Dr. B.F. Hoyer (1)
  T. D枚rner (1)
  
  1. Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie ; Charit茅 鈥?Universit盲tsmedizin Berlin ; Campus Charit茅 Mitte ; Charit茅platz 1 ; 10117 ; Berlin ; Deutschland
  
• 关键词：Systemischer Lupus erythematodes ; Biologika ; B ; Zellen ; Lymphozytendepletion ; Belimumab ; Systemic lupus erythematosus ; Biologics ; B ; cells ; Lymphocyte depletion ; Belimumab
• 刊名：Zeitschrift f篓鹿r Rheumatologie
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：74
• 期：3
• 页码：206-214
• 全文大小：599 KB
• 参考文献：1. Aringer, (2004) Arthritis Rheum 50: pp. 3161 CrossRef
  2. Aringer, (2009) Rheumatology 48: pp. 1451 CrossRef
  3. Ball, (2014) Lupus 23: pp. 46 CrossRef
  4. Bertsias, (2008) Ann Rheum Dis 67: pp. 195 CrossRef
  5. Cardiel, (2008) Arthritis Rheum 58: pp. 2470 CrossRef
  6. Condon, (2013) Ann Rheum Dis 72: pp. 1280 CrossRef
  7. Daridon, (2010) Arthritis Res Ther 12: pp. R204 CrossRef
  8. Dorner, (2006) Arthritis Res Ther 8: pp. R74 CrossRef
  9. Dorner, (2010) Pharmacol Ther 125: pp. 464 CrossRef
  10. Ezeonyeji, (2012) Rheumatology 51: pp. 476 CrossRef
  11. Furie, (2014) Arthritis Rheumatol 66: pp. 379 CrossRef
  12. Furie RA, Leon G, Thomas M et al (2014) A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis (Epub ahead of print)
  13. Ginzler, (2012) Arthritis Res Ther 14: pp. R33 CrossRef
  14. Group, (2014) Arthritis Rheumatol 66: pp. 3096 CrossRef
  15. Hahn, (1998) N Engl J Med 338: pp. 1359 CrossRef
  16. Hahn, (2012) Arthritis Care Res: pp. 797 CrossRef
  17. Hiepe, (2011) Rheumatology 7: pp. 170
  18. Hoyer, (2004) J Exp Med 199: pp. 1577 CrossRef
  19. Humrich J, Spee-Mayer C, Siegert E et al (2014) Induction of clinical remission by low-dose interleukin-2 in refractory SLE. Arthritis Rheumatol (Epub ahead of print)
  20. Illei, (2010) Arthritis Rheum 62: pp. 542 CrossRef
  21. Inghirami, (1988) Clin Exp Rheumatol 6: pp. 269
  22. Isenberg, (2013) Ann Rheum Dis 72: pp. 258 CrossRef
  23. Jacobi, (2008) Ann Rheum Dis 67: pp. 450 CrossRef
  24. Kalunian, (2002) Arthritis Rheum 46: pp. 3251 CrossRef
  25. Kremer, (2003) N Engl J Med 349: pp. 1907 CrossRef
  26. Lauwerys, (2013) Arthritis Rheum 65: pp. 447 CrossRef
  27. Liossis, (2004) BioDrugs 18: pp. 95 CrossRef
  28. Maury, (1989) Arthritis Rheum 32: pp. 146 CrossRef
  29. Mcbride, (2012) Arthritis Rheum 64: pp. 3666 CrossRef
  30. Merrill, (2010) Arthritis Rheum 62: pp. 222 CrossRef
  31. Moreland, (2002) Arthritis Rheum 46: pp. 1470 CrossRef
  32. Muller, (2014) Rheumatology 10: pp. 422
  33. Murray, (2010) Clin Rheumatol 29: pp. 707 CrossRef
  34. Mysler, (2013) Arthritis Rheum 65: pp. 2368 CrossRef
  35. Oropallo, (2011) Drug Dev Res 72: pp. 779 CrossRef
  36. Parodis, (2014) Ann Rheum Dis 73: pp. 968 CrossRef
  37. Pena-Rossi, (2009) Lupus 18: pp. 547 CrossRef
  38. Pepper, (2009) Nephrol Dial Transplant 24: pp. 3717 CrossRef
  39. Petri, (2013) Arthritis Rheum 65: pp. 1011 CrossRef
  40. Powell, (2014) Ann Rheum Dis 73: pp. 75 CrossRef
  41. Ramos-Casals, (2007) Medicine 86: pp. 242 CrossRef
  42. Ripley, (2005) Ann Rheum Dis 64: pp. 849 CrossRef
  43. Rolink, (2002) Curr Opin Immunol 14: pp. 266 CrossRef
  44. Rose, (2013) Ann Rheum Dis 72: pp. 1639 CrossRef
  45. Rovin, (2012) Arthritis Rheum 64: pp. 1215 CrossRef
  46. Schwarting, (2014) Ann Rheum Dis 73: pp. 78 CrossRef
  47. Shirota, (2013) Ann Rheum Dis 72: pp. 118 CrossRef
  48. Studnicka-Benke, (1996) Br J Rheumatol 35: pp. 1067 CrossRef
  49. Tew, (2010) Lupus 19: pp. 146 CrossRef
  50. Tsai, (2000) Nephron 85: pp. 207 CrossRef
  51. Urowitz, (1997) J Rheumatol 24: pp. 1061
  52. Vollenhoven RF van, Aranow C, Rovin BH et al (2014) A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of sirakumumab in patients with active lupus nephritis. Ann Rheum Dis 73 (Epub ahead of print)
  53. Wallace, (2014) Ann Rheum Dis 73: pp. 183 CrossRef
  
• 刊物主题：Internal Medicine; Rheumatology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1435-1250

文摘

Background Improved understanding of the immunopathogenesis of systemic lupus erythematosus (SLE) has paved the way for new specific immune interventions for this inflammatory disease similar to those for rheumatoid arthritis and spondylarthritides. Methods New biologics were developed on this basis or are in the process of clinical development and open up new therapy options for patients. In this context belimumab is of particular importance. As an innovative biologic the monoclonal antibody against the cytokine BAFF/BLyS (belimumab) has been approved for the treatment of serologically active SLE. A number of other biologics against other cytokines are in the clinical development phase and appear to be promising for further improvement of the current therapeutic possibilities in SLE. This article addresses the current aspects of immune interventions with biologics for SLE and the specific challenges of this disease.